Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India

Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv HYDERABAD, March 19 (Reuters) - India's market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk's (NOVOb.CO), opens new tabpatent on semaglutide expires this week, triggering a wave of cheaper generics from local drugmakers and worries about uneven oversight in an over ...